New RSV protections for infants hit cost, insurance hurdles in U.S. rollout
Pfizer’s maternal vaccine, Abrysvo, and Sanofi’s monoclonal antibody, Beyfortus, were approved for expectant mothers and infants in the U.S. earlier this year.
This European biotech company could rally nearly 45%, says Morgan Stanley
Morgan Stanley is bullish on pelabresib, currently awaiting results from its Phase 3 MANIFEST-2 trial.
Meta says it’s stepping up misinformation enforcement during Israel-Hamas war
Meta created a special operations center with experts fluent in Hebrew and Arabic.
Philadelphia Fed President Harker advocates holding interest rates ‘where they are’
Harker said the Fed has made progress in bringing down prices without causing a surge in unemployment or otherwise tanking the economy.
Microsoft closes $69 billion acquisition of Activision Blizzard after lengthy regulatory review
More than 20 months after agreeing to the company’s largest purchase ever, Microsoft has closed its acquisition of Activision Blizzard
JPMorgan Chase CEO Jamie Dimon warns this is ‘the most dangerous time’ for the world in decades
The head of the largest U.S. bank by assets cited the ongoing war in Ukraine as well as the attacks Hamas launched on Israel last weekend.
Wolfe Research downgrades Netflix, says streaming giant’s growth forecasts raise concerns
Analyst Peter Supino said the company’s premium valuation does not provide enough safety to counter the rising risk of reduced growth.
Morgan Stanley downgrades this Chinese e-commerce stock on weak consumer demand
The firm lowered its rating on shares to equal weight from overweight and slashed its price target approximately 40%.
JPMorgan says this packaged food company can rally 25% due to strong cash flow
The firm initiated coverage on Post Holdings with an overweight rating.
Buy this beaten-down discount retailer after a major leadership change, Gordon Haskett says
Analyst Chuck Grom upgraded shares to buy from hold in a Friday note.
